Following the acquisition of 52.34% of the Company’s shares by the tender offeror, delisting is scheduled on April 24, 2026. The stock consolidation will merge 7,253,607 shares into 2 shares, reducing the number of issued shares by 37,856,768 to 10 shares.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3902","jir_company_name":"Medical Data Vision Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-02-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/3902-20260227-01.pdf","jir_short_summary":"Following the acquisition of 52.34% of the Company's shares by the tender offeror, delisting is scheduled on April 24, 2026. The stock consolidation will merge 7,253,607 shares into 2 shares, reducing the number of issued shares by 37,856,768 to 10 shares.","jir_summary":"### Overview of Stock Consolidation and Tender Offer\nMedical Data Vision Co., Ltd. plans to hold an extraordinary shareholders' meeting on March 24, 2026, following the acquisition of 52.34% of the Company's shares by the tender offeror, Nippon Life Insurance Company. At the meeting, a resolution will be passed to consolidate 7,253,607 shares into 2 shares. Consequently, the total number of issued shares will decrease by 37,856,768, resulting in 10 shares after the change takes effect. The tender offer price is set at 1,693 JPY per share, representing a 266.45% premium over the Tokyo Stock Exchange Prime Market closing price of 462 JPY. A fairness opinion from Akasaka International Accounting has also been obtained.\n\n### Delisting and Impact on Shareholders\nAs a result of the stock consolidation, the Company's shares are scheduled to be delisted from the Tokyo Stock Exchange on April 24, 2026. After delisting, trading of the Company's shares will no longer be possible. Fractional shares resulting from the stock consolidation will be sold to the tender offeror with court approval, and the proceeds will be distributed to shareholders. The amount for fractional shares will be based on the tender offer price of 1,693 JPY per share, ensuring shareholders are not disadvantaged. The disadvantages associated with going private are deemed limited, and synergies with the tender offeror are expected to enhance corporate value.\n\n### Fairness Assurance Measures and Establishment of an Independent Committee\nThis transaction follows the Corporate Acquisition Guidelines and Fair M&A Guidelines, with a special committee of three independent outside directors established to ensure fairness and avoid conflicts of interest. Stock valuation and fairness opinions were obtained from the third-party valuation firm Akasaka International Accounting, with SBI Securities appointed as the financial advisor. The Board of Directors has fully respected the recommendations of the special committee, endorsing the tender offer and recommending shareholders to participate.\n\n### Upcoming Schedule and Amendment to Articles of Incorporation\nThe extraordinary shareholders' meeting is scheduled for March 24, 2026, to consider the stock consolidation, abolition of the unit share system, and partial amendments to the articles of incorporation. The effective date is planned for April 28, 2026. The amendments will reduce the total number of authorized shares to 40 and abolish the unit share system. Consequently, the Company will become a private company, with its shareholder base limited to the tender offeror and shareholders who agree not to participate.","jir_financial_highlights":"Total Number of Issued Shares (Before Effectiveness): 37,856,778 shares (Issued shares as of December 31, 2025: 40,027,526 shares less treasury shares of 2,170,748 shares)\nTotal Number of Issued Shares (After Effectiveness): 10 shares (Significant reduction due to stock consolidation)\nShares Held by Tender Offeror: 20,082,496 shares (Ownership ratio of 52.34%)\nTender Offer Price: 1,693 JPY\/share (266.45% premium to the Tokyo Stock Exchange Prime Market closing price of 462 JPY)\nScheduled Delisting Date: April 24, 2026 (Designated as a restructuring stock from March 24, 2026, to April 23, 2026)","jir_category":"","jir_hashtags":"#MedicalDataVision, #CapitalPolicy, #StockConsolidation, #Delisting, #TOB","jir_key_figures":"Shares Held by Tender Offeror: 20,082,496 shares (Ownership ratio 52.34%)\nStock Consolidation Ratio: 7,253,607 shares consolidated into 2 shares\nTender Offer Price: 1,693 JPY (266.45% premium over Tokyo Stock Exchange closing price of 462 JPY)","jir_meta_title":"Medical Data Vision Announces Stock Consolidation and Delisting with Tender Offer Price 1,693 JPY and 266.45% Premium","jir_meta_description":"Medical Data Vision is scheduled for delisting on April 24, 2026, following Nippon Life Insurance Company's acquisition of 52.34% of shares. Stock consolidation will significantly reduce issued shares, with a tender offer price of 1,693 JPY representing a 266.45% premium over market price.","jir_og_title":"Medical Data Vision Announces Stock Consolidation and Delisting","jir_og_description":"Following acquisition of 52.34% shares by tender offeror, delisting is scheduled on April 24, 2026. Stock consolidation merges 7,253,607 shares into 2 shares with a tender offer price of 1,693 JPY.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17052,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-31932","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n